ZHEJIANG MEDICINE CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.97 CNY | +3.85% |
|
+8.02% | -7.08% |
| Apr. 25 | Zhejiang Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 2023 | Zhejiang Medicine Wins Nod to Trial Digestive Acid Drug | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The company appears to be poorly valued given its net asset value.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -7.08% | 1.32B | C+ | ||
| +34.00% | 704B | C+ | ||
| +29.29% | 577B | B | ||
| -7.75% | 348B | C+ | ||
| +18.53% | 327B | B- | ||
| +4.95% | 288B | C+ | ||
| +13.79% | 234B | B+ | ||
| +4.93% | 198B | B- | ||
| -9.78% | 194B | A+ | ||
| -4.89% | 147B | C+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 600216 Stock
- Ratings Zhejiang Medicine Co., Ltd.
